Physician profile
Cono M Grasso
NPI 1609808393
$2,189.73
in general payments reported to CMS, 2019-2025
16 companies · $557 in 2025
The $557 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.54 · 2020: $186 · 2021: $258 · 2022: $531 · 2023: $329 · 2024: $306 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,104 · Education: $87.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,103.79 |
| Education | $87.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $1,020.94 | 2020-2025 | Acthar |
| Oyster Point Pharma, INC. | $214.70 | 2022-2025 | Tyrvaya, Ryzumvi |
| Kala Pharmaceuticals, INC. | $136.13 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $122.59 | 2022-2025 | Cequa |
| Harrow Eye, LLC | $108.35 | 2025 | Vevye |
| Bausch & Lomb Americas INC. | $94.83 | 2022-2024 | Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $94.41 | 2020-2021 | |
| Alcon Vision LLC | $79.36 | 2023-2025 | Eysuvis, Centurion, Simbrinza |
| Dompe US, INC. | $79.20 | 2022-2025 | Oxervate |
| Abbvie INC. | $65.80 | 2022-2024 | |
| Eyepoint US, INC. | $64.51 | 2020-2021 | |
| Allergan, INC. | $24.61 | 2021 | |
| Aerie Pharmaceuticals, INC. | $23.54 | 2019 | |
| Eyevance Pharmaceuticals LLC | $22.70 | 2022 | |
| Biotissue Holdings INC. | $20.91 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $17.15 | 2025 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cono Grasso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.